Fujian Institute of Trational Chiness Medicine
Fuzhou, Fujian, 350003, China
Completed
NCT Number: NCT01940380
The Study of LTBP1 of Postmenopausal Women Osteoporosis Molecular Mechanism of Kidney Yang Deficiency Syndrome
Postmenopausal Osteoporosis is characterized by a decrease in bone mass as well as a deterioration of the bone architecture resulting in an increased risk of fracture,which is directly related to the lack of estrogen and also associated with a variety of genetic and acquired factors. Previous studies have found that POP molecular regulation mechanism of kidney Yang deficiency syndrome may be associated with LTBP1 gene expression.
This topic using RT-PCR and Western Blot detection POP of kidney Yang deficiency group and healthy group LTBP1 mRNA and proteion's expression level,validate LTBP1 relevance to POP the kidney Yang deficiency syndrome.To provide a scientific basis for clinical treatment.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
45 year–75 year
Sex eligibility
Female
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- • The Participants who volunteer to be test subjects, and can accept experimental drugs, and promise to finish the course should sign the informed consent.
- Female ages 45 to 75 had gone through natural menopause before two years
- In accordance with the western medicine diagnostic criteria of osteoporosis and belong to kidney Yin deficiency syndrome differentiation of traditional Chinese medicine certificate;
- In accordance with the western medicine diagnostic criteria;
- In accordance with TCM diagnostic methods; .If any of the above answers are no, The subjects couldn't in the study
Exclusion criteria
- Do not accord with standard of the western medicine diagnosis and TCM diagnostic methods
- Age: <44 and > 76 years old;
- With hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma and other serious complications such as secondary osteoporosis; Late or deformity, disability, loss of labor;
- With cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases;
- Psychosis or alzheimer's patients;
- Nearly three months, the use of hormone replacement therapy (HRT) and taking calcitonin, nearly six months has used double phosphonic acid salt for 15 days, etc.;
- This medicine allergic constitution or composition of known to have allergies;
- In a critical condition, It's difficult to make exact evaluators to efficacy and safety of the new drugs;
Treatment and study plan
Primary outcomes
-
Postmenopausal Osteoporosis of kidney Yang deficiency syndrome
Time frame: To observe the changes in gene expression(Day 1)
Sponsors and collaborators
Lead sponsor
Fujian Academy of Traditional Chinese Medicine
Other
Registry information
Important dates
- Study start
- 2013
- Primary completion
- 2013
- Study completion
- 2016
- First posted
- Sep 12, 2013
- Registry last updated
- Mar 21, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.